Jason B Cohen, MD
Nuclear Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cohen’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74986 · Current
Licensed to practise in California · since 2001 · expires 2027-06-30 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$871,458
Medicare paid this office $871,458 for 449 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 246 | $429,116 | $1,389 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 24 | $109,422 | $495 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 256 | $89,274 | $274 |
| Nuclear medicine study whole body with ct scan | 39 | $67,113 | $1,342 |
| Nuclear medicine study of brain with metabolic evaluation | 21 | $20,294 | $966 |
See all 7 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 246 | $429,116 | $1,389 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 24 | $109,422 | $495 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 256 | $89,274 | $274 |
| Nuclear medicine study whole body with ct scan | 39 | $67,113 | $1,342 |
| Nuclear medicine study of brain with metabolic evaluation | 21 | $20,294 | $966 |
| Dxa bone density measurement of hip, pelvis, spine | 67 | $2,882 | $43 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 11 | $129 | $12 |
Who their Medicare patients are
449 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 11% · Women 58% · Also on Medicaid 22% · Health risk score 1.87. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 75% · Cancer 46% · Diabetes 31% · Chronic kidney disease 31% · Coronary heart disease 27% · Depression 24% · COPD 22% · Atrial fibrillation 19% · Heart failure 16% · Dementia 8% · Stroke 7%.
The office billed $3,470,075, Medicare allowed $1,096,176 and paid $871,458; for 2,135 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 449 | 2,135 | 74 | 1.87 | $3,470,075 | $871,458 |
| 2023 | 548 | 1,970 | 75 | 1.89 | $3,880,895 | $1,014,432 |
| 2022 | 585 | 2,229 | 75 | 1.93 | $3,467,150 | $957,548 |
| 2021 | 595 | 2,760 | 75 | 2.09 | $3,794,365 | $990,053 |
| 2020 | 545 | 2,779 | 74 | 2.08 | $3,855,998 | $929,905 |
| 2019 | 551 | 2,417 | 73 | 2.11 | $3,836,815 | $922,999 |
| 2018 | 896 | 2,802 | 73 | 1.74 | $3,915,299 | $947,479 |
| 2017 | 1,314 | 2,284 | 73 | 1.44 | $3,178,965 | $719,704 |
| 2016 | 1,450 | 2,304 | 73 | 1.32 | $3,712,397 | $817,754 |
| 2015 | 906 | 2,174 | 73 | 1.37 | $3,113,528 | $717,403 |
| 2014 | 276 | 646 | 73 | 1.45 | $649,196 | $234,896 |
| 2013 | 47 | 428 | 74 | 1.79 | $84,240 | $35,685 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 312 | $497,669 | $1,334 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 27 | $135,307 | $488 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 340 | $118,037 | $286 |
| Nuclear medicine study whole body with ct scan | 69 | $114,149 | $1,409 |
| Nuclear medicine study of brain with metabolic evaluation | 15 | $10,103 | $631 |
| Nuclear medicine study of bone and/or joint whole body | 11 | $2,654 | $241 |
| Dxa bone density measurement of hip, pelvis, spine | 62 | $2,630 | $42 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 11 | $566 | $51 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 19 | $226 | $12 |
2022: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 316 | $469,952 | $1,374 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 338 | $106,409 | $286 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 18 | $82,944 | $471 |
| Nuclear medicine study whole body with ct scan | 45 | $72,205 | $1,389 |
| Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days | 18 | $13,911 | $773 |
| Nuclear medicine study of brain with metabolic evaluation | 11 | $12,326 | $1,121 |
| Nuclear medicine study of bone and/or joint whole body | 20 | $4,994 | $250 |
| Dxa bone density measurement of hip, pelvis, spine | 75 | $3,025 | $40 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 19 | $1,096 | $58 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 32 | $379 | $12 |
2021: 8 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 325 | $509,726 | $1,367 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 378 | $119,015 | $271 |
| Nuclear medicine study whole body with ct scan | 63 | $103,872 | $1,385 |
| Nuclear medicine study of bone and/or joint whole body | 37 | $9,772 | $264 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 21 | $1,152 | $55 |
| Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days | 11 | $924 | $84 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 54 | $648 | $12 |
| Nuclear medicine study of liver and bile duct system | 11 | $329 | $30 |
2020: 7 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 371 | $552,012 | $1,337 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 423 | $93,918 | $202 |
| Nuclear medicine study whole body with ct scan | 57 | $76,959 | $1,304 |
| Nuclear medicine study of brain with metabolic evaluation | 21 | $23,507 | $1,119 |
| Nuclear medicine study of bone and/or joint whole body | 16 | $4,274 | $267 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 11 | $755 | $63 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 25 | $300 | $12 |
2019: 6 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 403 | $523,927 | $1,236 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 431 | $90,961 | $199 |
| Nuclear medicine study whole body with ct scan | 65 | $84,599 | $1,263 |
| Fluciclovine f-18, diagnostic, 1 millicurie | 21 | $73,017 | $348 |
| Nuclear medicine study of lung ventilation and circulation | 16 | $708 | $44 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 12 | $142 | $12 |
2018: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 431 | $535,682 | $1,170 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 446 | $93,402 | $196 |
| Nuclear medicine study whole body with ct scan | 55 | $67,263 | $1,160 |
| Dxa bone density measurement of hip, pelvis, spine | 218 | $9,647 | $44 |
| Nuclear medicine study of bone taken at different times | 18 | $5,544 | $308 |
| Nuclear medicine study of bone and/or joint whole body | 21 | $5,528 | $263 |
| Nuclear medicine study of lung ventilation and circulation | 24 | $1,038 | $43 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 41 | $476 | $12 |
| Nuclear medicine study of bone taken at different times | 12 | $458 | $38 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 12 | $387 | $32 |
2017: 10 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 382 | $478,329 | $1,150 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 409 | $86,703 | $195 |
| Nuclear medicine study whole body with ct scan | 40 | $51,189 | $1,190 |
| Dxa bone density measurement of hip, pelvis, spine | 630 | $27,311 | $43 |
| Nuclear medicine study of bone and/or joint whole body | 36 | $7,815 | $217 |
| Nuclear medicine study of bone taken at different times | 13 | $3,930 | $302 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 66 | $2,710 | $41 |
| Nuclear medicine study of lung ventilation and circulation | 28 | $1,196 | $43 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 49 | $569 | $12 |
| Dxa bone density measurement of hip, pelvis, spine | 13 | $136 | $10 |
2016: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 434 | $559,153 | $1,136 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 462 | $102,128 | $195 |
| Nuclear medicine study whole body with ct scan | 34 | $41,336 | $1,148 |
| Dxa bone density measurement of hip, pelvis, spine | 720 | $31,137 | $43 |
| Nuclear medicine study of brain with metabolic evaluation | 13 | $14,908 | $1,147 |
| Nuclear medicine study of bone and/or joint whole body | 21 | $4,558 | $217 |
| Nuclear medicine study of bone taken at different times | 15 | $4,497 | $300 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 81 | $3,425 | $42 |
| Nuclear medicine study of lung ventilation and circulation | 27 | $1,167 | $43 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 11 | $1,079 | $98 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 37 | $430 | $12 |
| Dxa bone density measurement of hip, pelvis, spine | 35 | $367 | $10 |
2015: 15 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 346 | $444,049 | $1,184 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 377 | $79,602 | $196 |
| Nuclear medicine study whole body with ct scan | 38 | $48,139 | $1,203 |
| Dxa bone density measurement of hip, pelvis, spine | 304 | $13,285 | $44 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 20 | $8,351 | $418 |
| Nuclear medicine study of bone and/or joint whole body | 36 | $7,941 | $221 |
| Nuclear medicine study of bone taken at different times | 22 | $6,832 | $297 |
| Nuclear medicine study of brain | 13 | $4,453 | $318 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 17 | $2,705 | $87 |
| Injection, regadenoson, 0.1 mg | 13 | $2,028 | None |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 46 | $1,985 | $43 |
| Iodine i-123 sodium iodide, diagnostic, per 100 microcuries, up to 999 microcuries | 26 | $1,791 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 16 | $885 | $55 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 62 | $709 | $11 |
| Dxa bone density measurement of hip, pelvis, spine | 12 | $126 | $11 |
2014: 12 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 83 | $116,096 | $1,304 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 95 | $19,466 | $193 |
| Nuclear medicine study whole body with ct scan | 11 | $14,765 | $1,342 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 30 | $13,060 | $435 |
| Dxa bone density measurement of hip, pelvis, spine | 97 | $5,623 | $57 |
| Nuclear medicine study of bone and/or joint whole body | 16 | $4,001 | $235 |
| Injection, regadenoson, 0.1 mg | 15 | $2,481 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 19 | $1,956 | $103 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 13 | $1,916 | $87 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 13 | $872 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 13 | $711 | $55 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 17 | $251 | $14 |
2013: 3 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 15 | $16,598 | $1,107 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $3,920 | $196 |
| Dxa bone density measurement of hip, pelvis, spine | 16 | $937 | $59 |
Medicaid work
$35,766 in 2024
Medicaid paid $35,766 for 62 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 35 | $27,922 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 27 | $7,844 |
| 2024 | 62 | 2 | 14 | $35,766 |
| 2023 | 28 | 2 | 13 | $13,125 |
| 2022 | 46 | 2 | 14 | $16,108 |
| 2021 | 29 | 2 | 12 | $9,805 |
| 2020 | 156 | 2 | 22 | $25,366 |
| 2019 | 314 | 2 | 25 | $52,981 |
| 2018 | 369 | 2 | 21 | $120,722 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 16 | $9,985 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 12 | $3,140 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 21 | $12,244 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 25 | $3,864 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 17 | $8,204 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 12 | $1,601 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 77 | $19,028 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 79 | $6,339 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 195 | $46,677 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 119 | $6,304 |
2018
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 222 | $108,428 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 147 | $12,294 |
Money from drug and device companies
$28 in 2024
| 2024 | 1 | 1 | None | $28 |
| 2021 | 1 | 1 | None | $100 |
| 2020 | 2 | 3 | None | $101 |
| 2019 | 2 | 2 | None | $73 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Amplatzer Amulet | $28 | 1 payment
|
See the published payment
| Abbott Laboratories | Meals · 2024-10-02 | Amplatzer Amulet | $28 |
See earlier years (2021, 2020, 2019)
2021: $100
| Astellas Pharma US | None | $100 | 1 payment
|
2020: $101
| Baxter Healthcare | Floseal | $76 | 2 payments
|
| Pacira Pharmaceuticals | Exparel | $25 | 1 payment
|
2019: $73
| Baxter Healthcare | Tisseel | $48 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $25 | 1 payment
|
Professional record
- NPI
- 1902846561
- Licence
- CA A74986California A74986: Current · expires 2027-06-30
- Trained
- University of Michigan Medical School, 1999
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A749860
- Taxonomy
- Federal specialty code 207U00000X (207U00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-06-08
- NPI last updated
- 2025-02-28
- NPI record certified
- 2025-02-28
This is when the NPI record was last certified, not a medical board exam.